OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Psychiatry is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Treating Pathologies of the Will	235
Evaluating Associations Between Cannabis and Heroin Use	188
Broadening the Parameters of Clinical High Risk for Psychosis	162
2024 Annual Meeting: Presidential Address	153
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	152
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	140
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	137
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	128
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	120
Mental Health Disparities Research: An Introduction to New Directions	118
Reconsidering the Interpretive Basis of Neural Efficiency as a Biomarker in Pediatric Anxiety: Response to Ai and Colleagues	111
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	107
Depression, Inflammation, and Postpartum Psychosis	103
Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions	99
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	98
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	97
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	93
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	90
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	89
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	79
Correcting Overestimations in Self-Harm Visit Data	77
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	76
Correction to Poirot et al.	75
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	75
Corrigendum to Morley et al.	73

Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	72
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	72
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	71
2024 Annual Meeting: CEO and Medical Director’s Address	68
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	66
The First Large GWAS Meta-Analysis for Postpartum Depression	65
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	64
Highlights From the Residents’ Journal: September 2024	63
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	62
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	62
Familial Risk of Postpartum Psychosis	61
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	60
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	58
New Insights Into Psychotic Disorders	58
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	57
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	56
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	55
Suicide and the Menstrual Cycle	53
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	52
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	52
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	52
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	52
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	52
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	50
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	49